Yes. The existence of human review does not automatically reduce regulatory expectations. Inspectors often focus on how heavily personnel rely on the AI output rather than who clicks the final approval button.

A recurring concern appears when users consistently accept AI-generated recommendations with little independent evaluation. During reviews, organizations may describe the system as "advisory only," yet records show that recommendations are rarely challenged or modified. That creates questions about whether the AI has become a de facto decision-maker.

Evidence that carries weight includes documented review criteria, examples of rejected recommendations, user training records, escalation pathways, and clear definitions of when human intervention is required. Reviewers frequently ask how personnel recognize incorrect, incomplete, or unreasonable outputs.

When AI recommendations influence batch disposition, investigations, deviations, complaint assessments, or quality decisions, documented oversight becomes difficult to defend if the organization cannot demonstrate meaningful human evaluation rather than procedural signoff.

The largest exposure often comes from assuming that supplier qualification ends once a contract is signed. Inspectors frequently look beyond procurement records and ask how the organization understands changes occurring within the AI service itself.

A vendor may update models, retrain algorithms, modify data handling practices, change security controls, or alter system functionality without obvious impact to end users. Those changes can affect output reliability while remaining largely invisible to the regulated company.

Inspection discussions become uncomfortable when teams cannot explain what information they receive about model updates, performance changes, known limitations, or issue management. Statements such as "the vendor handles that" rarely satisfy questions involving product quality or GMP-relevant activities.

Stronger positions are supported by documented supplier oversight, defined notification requirements, periodic performance reviews, contractual transparency expectations, and evidence that significant vendor changes are evaluated through established quality processes. Responsibility for GMP compliance remains with the regulated organization regardless of where the AI technology originates.

Documentation often focuses on whether the AI produced the expected answer during testing. Far less attention is given to demonstrating why the answer should be trusted under changing operational conditions.

Inspection friction develops when an organization can show successful examples but cannot explain how performance is monitored after deployment. Historical accuracy data, exception trends, false positive rates, false negative rates, challenge testing results, and periodic effectiveness reviews are frequently absent.

Experienced reviewers tend to examine difficult cases rather than successful ones. They look for examples where the system struggled, produced questionable recommendations, or required correction. Those records reveal whether the organization truly understands the system's limitations.

Confidence becomes more defensible when supported by ongoing evidence rather than one-time validation activities. Organizations that maintain performance metrics, investigate unexpected outputs, document user feedback, and periodically reassess suitability generally provide a more convincing explanation than those relying solely on initial implementation records.

The transition occurs when AI begins influencing how quality-related decisions are made across functions. At that point, questions extend beyond software management and enter areas of accountability, authority, oversight, and organizational control.

A frequent operational failure point appears when different departments deploy AI independently. Quality may use one tool for investigations, manufacturing another for operational analysis, training a separate platform for learning content, and regulatory affairs yet another for document preparation. Each deployment may appear reasonable in isolation while creating inconsistent standards across the organization.

Governance concerns emerge when there is no defined ownership for acceptable use, risk evaluation, approval criteria, monitoring expectations, or escalation of AI-related issues. Inspectors often examine whether responsibilities are clearly assigned and whether management understands where AI is being used in GMP-relevant activities.

Organizations generally defend AI adoption more effectively when oversight is coordinated through established quality and management systems rather than left entirely to individual departments or technology teams.